Xenon Pharmaceuticals targets a Q3 2026 NDA submission for AZK, with commercial launch planned for late 2027 or early 2028.
Xenon Pharmaceuticals announced plans to file a New Drug Application for AZK in Q3 2026, positioning the therapy for a potential commercial launch in late 2027 or early 2028. The timeline reflects progress in Phase III trials and aligns with the company’s strategy to expand its neuroscience portfolio.
During its Q1 2026 earnings call, management highlighted strong operational momentum, though no specific financial or clinical data were disclosed. The company’s focus remains on advancing AZK through regulatory milestones, with prior updates indicating robust pipeline development.
Shares of XENE showed limited immediate reaction to the announcement, as investors await further details on clinical efficacy and market potential.